Deslee Gaétan, Fabry-Vendrand Caroline, Salmi Elsa, Poccardi Nolwenn, Coriat Adrien, Ghout Idir, Eteve-Pitsaer Caroline, Adderley Nicola J, Leleu Henri
Service de Pneumologie, INSERM UMRS-1250, Centre Hospitalier Universitaire de Reims, Université Reims, Champagne-Ardenne, France.
AstraZeneca, Courbevoie, France.
Int J Chron Obstruct Pulmon Dis. 2025 Apr 18;20:1131-1142. doi: 10.2147/COPD.S495086. eCollection 2025.
Budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR) single inhaler triple therapy became available to prescribe to patients with severe chronic obstructive pulmonary disease (COPD) in France in 2021. The characteristics of patients prescribed BUD/GLY/FOR triple therapy and guideline adherence have not been previously described in France.
To describe the characteristics of COPD patients initiated on BUD/GLY/FOR triple therapy, assess adherence to COPD management guidelines, and explore any differences by prescribing physician.
A cross-sectional study using data from The Health Improvement Network (THIN) France database was conducted. Patients with ≥2 recorded diagnostic codes for COPD were included. Demographic characteristics, comorbidities, management, COPD-related characteristics, and guideline adherence (Société de Pneumologie de Langue Française (SPLF); Haute Autorité de Santé (HAS)), stratified by initiating physician speciality (general practitioner (GP) or pulmonologist) were described.
A total of 263 patients initiating BUD/GLY/FOR triple therapy were included. Mean (SD) age was 68.8 (11.8) years; 53.6% were male. Mean (SD) COPD duration was 6.4 (5.5) years. Comorbidities were common, with slightly more cardiometabolic and mental health conditions recorded in the GP-initiated group, and more comorbid respiratory conditions recorded in the pulmonologist-initiated group. About 77.2% (n=203) of patients had at least one moderate or severe exacerbation in the 12 months before initiation. About 86.3% had a previous record of dual (n=117, 44.5%) or triple (n=110, 41.8%) therapy. About 68.8% had been initiated on BUD/GLY/FOR triple therapy in line with SPLF guidelines (62.4% and 72.4% in the GP- and pulmonologist-initiated groups, respectively); among those with a record of COPD severity, 75.2% were initiated in line with HAS guidelines (69.2% and 76.3% in the GP- and pulmonologist-initiated groups, respectively).
The majority of COPD patients are prescribed BUD/GLY/FOR triple therapy in accordance with current treatment guidelines, irrespective of whether the therapy is prescribed by a general practitioner or a pulmonologist.
布地奈德/格隆溴铵/富马酸福莫特罗（BUD/GLY/FOR）单吸入器三联疗法于2021年在法国可供医生为重度慢性阻塞性肺疾病（COPD）患者开具处方。此前法国尚未描述过接受BUD/GLY/FOR三联疗法患者的特征以及对指南的依从性。
描述开始接受BUD/GLY/FOR三联疗法的COPD患者的特征，评估对COPD管理指南的依从性，并探讨开处方医生之间的差异。
利用法国健康改善网络（THIN）数据库的数据进行了一项横断面研究。纳入有≥2条COPD诊断编码记录的患者。描述了人口统计学特征、合并症、治疗情况、COPD相关特征以及指南依从性（法国语言医学会（SPLF）；法国卫生高级管理局（HAS）），并按开处方医生的专业（全科医生（GP）或肺科医生）进行分层。
共纳入263例开始接受BUD/GLY/FOR三联疗法的患者。平均（标准差）年龄为68.8（11.8）岁；53.6%为男性。COPD平均（标准差）病程为6.4（5.5）年。合并症很常见，全科医生开处方组记录的心脏代谢和心理健康状况略多，肺科医生开处方组记录的合并呼吸系统疾病更多。在开始治疗前的12个月内，约77.2%（n = 203）的患者至少有一次中度或重度加重。约86.3%的患者有双联（n = 117，44.5%）或三联（n = 110，41.8%）治疗史。约68.8%的患者开始接受BUD/GLY/FOR三联疗法符合SPLF指南（全科医生开处方组和肺科医生开处方组分别为62.4%和72.4%）；在有COPD严重程度记录的患者中，75.2%的患者开始治疗符合HAS指南（全科医生开处方组和肺科医生开处方组分别为69.2%和76.3%）。
大多数COPD患者接受BUD/GLY/FOR三联疗法的处方符合当前治疗指南，无论该疗法是由全科医生还是肺科医生开具。
